DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Household
Published
26 Dec 24
Updated
24 Jun 26
Views
97
Not Invested
Emami531162
531162 logo
Fair Value
₹545.05
Share price24 Jun
₹368.332.4% undervalued intrinsic discount
Loading
1Y-36.51%
7D1.21%

Rural Recovery And Digital Channels Will Deliver Value

AN
AnalystConsensusTarget
AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
26 Dec 24
Updated
24 Jun 26
Views
97
Not Invested
Fair Value₹545.05
Share price₹368.3
32.4% undervalued intrinsic discount
Narrative
Updates15

Last Update 24 Jun 26

Fair value Decreased 14%

531162: May Board Meeting And Leadership Review Will Support Bullish Outlook

Analysts have trimmed their price target on Emami to ₹545 from about ₹637, citing refreshed assumptions around slightly higher discount rates, more moderate revenue growth, softer profit margins, and a lower future P/E multiple.

What’s in the News for Emami

  • Emami has scheduled a Board meeting on May 21, 2026, at 12:00 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. (Source: Company filing)
  • The Board will review the reappointment of Shri Harsha Vardhan Agarwal as Vice Chairman and Managing Director for an additional 5-year term after his current term ends on March 31, 2027, subject to shareholder approval at the next Annual General Meeting. (Source: Company filing)
  • Reappointment of M/s. V. K. Jain & Co. as Cost Auditors for the financial year 2026–27 is on the agenda under Section 148(3) of the Companies Act, 2013. (Source: Company filing)
  • The Board may also consider other matters that arise during the May 21, 2026 meeting. (Source: Company filing)

Valuation Changes for Emami

  • Fair Value: Revised lower from ₹637.33 to ₹545.05, indicating a meaningful cut to the estimated intrinsic value for Emami.
  • Discount Rate: Adjusted slightly higher from 12.68% to 12.80%, reflecting a modestly more cautious return requirement.
  • Revenue Growth: Assumption trimmed from 9.03% to 8.74%, pointing to a slightly more moderate growth outlook in the model for Emami.
  • Net Profit Margin: Forecast reduced from 21.76% to 20.65%, implying a softer expected profitability level in the updated estimates.
  • Future P/E: Target multiple lowered from 36.93x to 33.91x, suggesting the stock is now valued on a more moderate earnings multiple in the model.
Read more
5 viewsusers have viewed this narrative update

Key Takeaways

  • Growth in rural demand, healthcare, and international expansion is expected to drive revenue diversification and resilience.
  • Innovation, digital channels, and premium product focus should enhance margins and accelerate category growth.
  • Weak demand, intense competition, limited diversification, and inconsistent brand investment threaten sustainable growth, margin stability, and long-term market share for Emami.

Catalysts

About Emami
    Manufactures and markets personal and healthcare products in India and internationally.
What are the underlying business or industry changes driving this perspective?
  • Early signs of rural demand recovery and robust growth in pain management and healthcare portfolios (aided by favorable monsoons) are likely to drive resilient volume and value growth in the medium term, impacting revenue positively.
  • Expanding presence in new international geographies, with encouraging initial traction outside Bangladesh and plans for further market entries, should diversify revenue streams and reduce reliance on the Indian market, supporting sustainable topline growth.
  • Strong consumer tailwinds in personal care and wellness, especially among the young, urbanizing demographic, paired with increased innovation and digital-first product launches, are expected to accelerate penetration and category growth, positively impacting both revenues and operating margins.
  • Continued scale-up of digital channels and quick commerce, which are growing at 3x YoY, will expand reach into new-age consumers and lower distribution costs, likely supporting margin expansion and higher operating leverage.
  • Strategic brand extensions, product relaunches (e.g., Kesh King, Smart & Handsome), and focus on high-margin health & wellness categories are set to capture demand shifts toward herbal, natural, and premium personal care, improving mix and supporting net margin expansion over time.
Emami Earnings and Revenue Growth

Emami Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Emami's revenue will grow by 8.7% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 20.5% today to 20.6% in 3 years time.
  • Analysts expect earnings to reach ₹10.0 billion (and earnings per share of ₹23.44) by about June 2029, up from ₹7.8 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting ₹11.6 billion in earnings, and the most bearish expecting ₹8.9 billion.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 34.0x on those 2029 earnings, up from 22.8x today. This future PE is lower than the current PE for the IN Personal Products industry at 36.8x.
  • Analysts expect the number of shares outstanding to decline by 0.08% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 12.8%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Persistently weak performance in key categories like talc, male grooming (including Smart & Handsome/The Man Company), and Kesh King-alongside reliance on relaunches and repositioning-signals ongoing difficulty in reviving demand, growing market share, and attracting new consumers, which could pressure top line revenue growth over the long term.
  • Intense competition from D2C brands and changing consumer preferences are driving category declines and eroding the competitive advantage of Emami's major brands, potentially threatening both revenue and net margins if innovation and customer acquisition efforts do not materially succeed.
  • Limited international diversification, with international business still under 20% of sales and exposed to volatility in specific markets (e.g., Bangladesh), leaves Emami vulnerable to India-specific macroeconomic or consumption shocks, raising the risk of future earnings volatility and hindering resilient topline expansion.
  • Relatively flat advertising and promotion (A&P) spending as a percentage of sales, despite aggressive new launches and need for strong brand building in underperforming and competitive categories, could blunt growth momentum and brand equity, ultimately restricting sustainable revenue and market share gains.
  • Over-reliance on favorable product mix and seasonal/macroeconomic factors (e.g., margin improvements driven by mix of high-margin pain management in a strong monsoon year, weak talc sales due to short summer) may not be sustainable; if commodity cost inflation or weak seasonal cycles return, both gross margins and earnings could face renewed pressure.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of ₹545.05 for Emami based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ₹675.0, and the most bearish reporting a price target of just ₹415.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be ₹48.6 billion, earnings will come to ₹10.0 billion, and it would be trading on a PE ratio of 34.0x, assuming you use a discount rate of 12.8%.
  • Given the current share price of ₹404.15, the analyst price target of ₹545.05 is 25.9% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Emami?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

531162 logo
Emami
45.1% undervalued intrinsic discount

Rising Digital Penetration And Indian Urbanization Will Fuel Ayurveda Demand

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 8 Jul
Read Narrative
531162 logo
Emami
11.3% undervalued intrinsic discount

Traditional Personal Care Will Underperform As Digital Rivals Advance

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 9 Jun
Read Narrative

Fair Value vs Share Price

₹545.05
vs ₹368.332.4% undervalued intrinsic discount
PastFuture049b2015201820212024202620272029Revenue ₹48.6bEarnings ₹10.0b
8.7%
Revenue growth
20.6%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Emami

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

6 star dividend payer with excellent balance sheet.

Market cap₹160.8b
PB5.5x
Estimated Growth8.8%
Dividend Yield3.3%
Full analysis

CEO & management

Harsha Agarwal
CEO
4.4yrs
CEO Tenure

Manufactures and markets personal and healthcare products in India and internationally.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide